Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of Zevalin consolidation versus MabThera maintenance after initial R-CHOP response in previously untreated follicular lymphoma
2007-006601-25Phase 2Completed
- Sponsor
- PETHEMA
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) comparing Zevalin consolidation with MabThera maintenance (2 arms). Primary endpoint: Progression-free survival. Started Feb 2008; status: completed.
02
Drugs
ibritumomab tiuxetanrituximabcyclophosphamide + doxorubicin + vincristine + prednisone + rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2007-006601-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006601-25.